Claim OwnershipHealthcare Unfiltered
Subscribed: 69Played: 2,501
Subscribe
© 2026 Healthcare Unfiltered
Description
Healthcare Unfiltered is an honest, raw, timely podcast tackling any and all topics in healthcare that affect stakeholders. Dr. Chadi Nabhan uses his dynamic conversational skills to challenge his guests to address controversial and important topics. He also brings on world renowned experts to discuss clinical advances in medicine.
264 Episodes
Reverse
Drs. Shaalan Beg, Shruti Patel, and Emil Lou—the “Only Oncologists in the Building”—offer an in-depth, clinically focused review of the most important research presented at the ASCO GI Annual Meeting. The conversation spans the rising incidence and outcomes of early-onset colorectal cancer, survivorship considerations, and a nuanced discussion of ctDNA in the adjuvant setting for high-risk stage II disease, including whether its role has evolved from purely prognostic to truly predictive. The...
In this cross-collaboration episode, Drs. Sam Armstrong and Karine Tawagi—hosts of the “Two Onc Docs” podcast—join the show to share their personal journeys into oncology and the inspiration behind launching a podcast for the oncology community. The conversation then expands into a candid, practical discussion of oncology career paths, offering fellows and early-career physicians real-world guidance on choosing a first job, negotiating contracts and compensation, evaluating mentorship, and ba...
VK Gadi, MD, PhD, of the University of Illinois Cancer Center, joins the show for a deep dive into antibody-drug conjugates (ADCs) in breast cancer, tracing the history and basic science that fueled their development and early interest in the field. Dr. Gadi breaks down where ADCs currently fit in breast cancer care, including key toxicities, evolving data presented at ESMO, and findings that may support FDA approval in early-stage and neoadjuvant HER2-positive disease. The conversation also ...
Returning guest Megan Melody, MD—lymphoma and CAR-T hematologist at Tampa General Hospital and the University of South Florida—joins the show for a practical, data-driven discussion on the evolving role of measurable residual disease (MRD) and circulating tumor DNA (ctDNA) in lymphoma. The conversation explores which lymphoma subtypes benefit most from MRD assessment, the available commercial assays and their sensitivity and specificity, how MRD and PET imaging should be used together (or not...
Returning guest Doug Flora, MD, LSSBB, practicing oncologist and healthcare innovator, joins the show to discuss his new book Rebooting Cancer Care and his pragmatic vision for how artificial intelligence is reshaping oncology today. Dr. Flora explores how AI is already being leveraged to accelerate drug discovery and development, redesign smarter clinical trials, and support more informed, efficient decision-making—while emphasizing that these tools are meant to augment and “save” the oncolo...
Chadi sits down with Gregory Vidal, MD, PhD, medical oncologist at the West Cancer Center, for a comprehensive, state-of-the-field discussion on triple-negative breast cancer (TNBC). Dr. Vidal walks listeners through how TNBC emerged as a diagnosis of exclusion, who is most commonly affected, current treatment paradigms and sequencing in early-stage and metastatic disease, and key considerations around surgery, recurrence risk, and unresolved questions. The conversation also explores modern d...
Jonathan Chen, MD, PhD—Assistant Professor of Medicine and Biomedical Informatics at Stanford University—joins the show and offers a pragmatic look at how data science and AI can be meaningfully integrated into everyday medical practice. He breaks down how complex clinical data can be translated into intuitive, real-world use cases, from algorithm-driven decision support in cancer diagnosis to recommendations that fit seamlessly into day-to-day clinician workflows. The conversation also explo...
Chadi sits down with Sanjay Juneja, MD—board-certified hematologist/oncologist, healthcare futurist, and physician executive—to demystify artificial intelligence and explain what it truly means for patient care today and in the years ahead. Dr. Juneja breaks down how AI is already influencing healthcare broadly and oncology specifically, from generative AI applications to emerging tools that can analyze voice patterns to estimate physiologic markers like glucose levels. They also explore wher...
In this reflective and wide-ranging conversation, ASCO President Robin Zon, MD, FACP, FASCO, looks back on the formative moments that led her to oncology and the grit required to build a thriving community-based research program while balancing the demands of leadership, motherhood, and clinical practice. She shares the path that took her from ASCO member and fellow in 1997 to the presidency, unpacking the three-pillar theme she crafted for her term and the accomplishments she’s most proud of...
Chadi sits down with Dr. Sairah Ahmed just ahead of the ASH Annual Meeting for a comprehensive deep dive into the state of Hodgkin Lymphoma management in 2026. Dr. Ahmed walks through how clinicians should interpret the newest data releases, revisits whether histologic subtyping still influences decision-making in an era increasingly shaped by biomarkers, and details her practical framework for approaching patients with stage I/II disease—including when and how radiation therapy still plays a...
Journalist Erin O’Hearn joins Chadi to share her deeply personal story as both a patient and a caregiver navigating the healthcare system for more than two decades. Drawing from her lived experiences, Erin reflects on how today’s advances in artificial intelligence could have supported her journey—easing the emotional and logistical burdens of care while improving communication and empathy between patients and providers. She offers a thoughtful and forward-looking take on the MAHA movement, a...
Chadi sits down with Dr. Debra Patt, Executive Vice President of Texas Oncology and President of the Community Oncology Alliance (COA), for an in-depth conversation about the evolving landscape of community oncology. Dr. Patt outlines her vision for bringing innovation and artificial intelligence into routine cancer care—addressing challenges from clinical decision-making to physician burnout—while ensuring equitable access to cutting-edge treatments across all practice settings. She also dis...
Chadi resumes his WCLC review with Dr. Eric Singhi of The University of Texas MD Anderson Cancer Center, exploring the most significant updates in mutation-driven lung cancer presented at this year’s meeting. The discussion dives into advances in sequencing and molecular profiling to identify actionable genomic alterations (AGAs) and how these findings are transforming both early- and late-stage treatment strategies. Dr. Singhi highlights key data from the ADAURA, TARGET, and NAUTIKA1 studies...
Dr. Estelamari Rodriguez, thoracic oncologist at the University of Miami’s Sylvester Comprehensive Cancer Center, joins the show to break down the latest advances in non-mutation driven and small cell lung cancer presented at the World Conference on Lung Cancer (WCLC) and how they translate into everyday clinical practice. She discusses pivotal studies including the ALCHEMIST trial exploring adjuvant therapy in ALK-fusion–positive early-stage lung cancer, PACIFIC-2 assessing concurrent immuno...
Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping t...
Returning guest Jill Feldman, a prominent lung cancer survivor and patient advocate, shares her reflections on the World Conference on Lung Cancer (WCLC) from a patient’s point of view. She discusses how patients and advocates interpret complex scientific data, why attending conferences like WCLC is vital for bridging the gap between research and real-world experience, and how the dialogue between scientists and patients continues to evolve. Jill also highlights key takeaways from the meeting...
Investigative journalist and New York Times bestselling author Gardiner Harris joins the podcast to dive deep into his groundbreaking book, “No More Tears: The Dark Secrets of Johnson & Johnson.” Harris recounts the extensive research and challenges behind uncovering how J&J—long regarded as a trusted “goliath” of American healthcare—played a far greater role in fueling the opioid epidemic than Purdue Pharma, a contribution he argues led to more than two million American deaths yet re...
Returning guest Anthony DiGiorgio, DO, a practicing neurosurgeon at UCSF and noted health policy commentator, takes a deep dive into the 340B Drug Pricing Program—one of the most consequential yet misunderstood mechanisms in US healthcare. He traces the program’s origins in the early 1990s, designed to help safety net hospitals stretch scarce federal resources to better serve vulnerable patients. Dr. DiGiorgio examines how, over time, many institutions have leveraged 340B as an ancillary reve...
Dr. Anand Patel, DO, founder of LV8 Health, walks us through the philosophy and mechanics of concierge-style longevity medicine. He explains how LV8 applies Medicine 3.0, combining precision diagnostics (DEXA, VO₂ max, resting metabolic rate, advanced blood panels) with regenerative and geroprotective therapies, nutrition, fitness, and sleep optimization. You’ll hear how he translates data from wearables and diagnostics into bespoke plans, how he helps patients sustain behavior change, and ho...
Gavin MacBeath, CEO of TScan Therapeutics, takes us inside his journey from scientist to biotech leader and what it means to build and run a therapeutic development company at the cutting edge of immuno-oncology. He breaks down how TScan’s platform works to discover and match T-cell receptors (TCRs) with their antigens, and why TCR-T therapies may provide distinct benefits over CAR-T approaches, especially when tackling solid tumors. He also discusses which diseases are most likely to respond...
Comments
Download from Google Play
Download from App Store
United States